The formulation and an expanded indication for Tivicay tablets are currently under review in Europe The US Food and Drug Administration has approved the first-ever dispersible tablet formulation of ...

Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

If approved, this new formulation of DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV – closing the gap between treatment options available for ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

* GSK - DOLUTEGRAVIR IS FIRST INTEGRASE INHIBITOR AVAILABLE AS A DISPERSIBLE TABLET FOR CHILDREN WEIGHING AT LEAST 3KG AND FROM FOUR WEEKS OF AGE Source text for Eikon: Further company coverage: Sign ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

A new excipient for orally disintegrating tablets not only imparts superior tablet characteristics, but has the added advantage of allowing users to maintain full control over their formulations, ...

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV Dolutegravir is the first ...

Deborah Waterhouse, CEO of ViiV Healthcare, said: "I am delighted that our innovative approach to science has enabled us to achieve FDA approval of the first-ever dispersible tablet formulation of ...